Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Searle CoKAR:SEARL +2.00%73 Days Payable is 81.50 as of Mar. 2026, which is 5% above its 10-year median of 77.97. GuruFocus rates KAR:SEARL with a GF Score™ of 73/100 and a GF Value™ of ₨76.13 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, The Searle Co ranks better than 55.02% on this metric.
The historical rank and industry rank for The Searle Co's Days Payable or its related term are showing as below:
KAR:SEARL'
s Days Payable Range Over the Past 10 Years
Min: 30.91 Med: 77.97 Max: 123.19
Current: 99.52
During the past 13 years, The Searle Co's highest Days Payable was 123.19. The lowest was 30.91. And the median was 77.97.
KAR:SEARL's Days Payable is ranked better than 55.02% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs KAR:SEARL: 99.52
The Searle Co's Days Payable
declined
from Mar. 2025 (160.17) to Mar. 2026 (81.50).
It may suggest that The Searle Coaccelerated paying its suppliers.
The Searle Co Days Payable Related Terms
The Searle Co Days Payable Historical Data
* Premium members only.
The historical data trend for The Searle Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:SEARL vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Searle Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Searle Co's Days Payable distribution charts can be found below:
* The bar in red indicates where The Searle Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
The Searle Co's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Searle Co (KAR:SEARL) has a Days Payable of 81.50 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on The Searle Co and its competitors. This is near median its historical median of 77.97. Over the past decade, The Searle Co's Days Payable has ranged from 30.91 to 123.19. According to the industry distribution chart, The Searle Co ranks #417 out of 927 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is The Searle Co's Days Payable too high?
The Searle Co's current Days Payable of 81.50 is near median its 10-year median of 77.97. Over the past 10 years, this metric has ranged from a low of 30.91 to a high of 123.19. The Drug Manufacturers industry median Days Payable is 90.38. The Searle Co's value of 81.50 is 9.8% below this industry median. Based on the distribution chart, The Searle Co ranks #417 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, The Searle Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Searle Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, The Searle Co ranks #417 out of 927 companies for Days Payable. This puts The Searle Co in the upper half of its industry. The industry median Days Payable is 90.38. The Searle Co's value of 81.50 is 9.8% below this benchmark. Historically, The Searle Co's own Days Payable has ranged from 30.91 to 123.19 over the past decade. While the company's 10-year median is 77.97 vs. the industry median of 90.38, The Searle Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Searle Co's current Days Payable of 81.50 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on The Searle Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Searle Co's current Days Payable is 81.50, which is near median its own 10-year median of 77.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Searle Co stock overvalued right now?
Based on GuruFocus' analysis, The Searle Co (KAR:SEARL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨76.13, compared to a current price of ₨92.30 — trading 21.2% above its estimated fair value. The current Days Payable is 81.50, which is near median its 10-year median of 77.97 and 9.8% below the Drug Manufacturers industry median of 90.38. The Searle Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For The Searle Co (KAR:SEARL), the current Days Payable is 81.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Searle Co (KAR:SEARL) Overvalued in 2026?
Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued.
The current stock price of ₨92.30 is trading 21.2% above its estimated GF Value™ of ₨76.13.
GuruFocus considers The Searle Co to be Modestly Overvalued.
Key valuation signals for KAR:SEARL:
Days Payable: 81.50 (near median its 10-year median of 77.97)
GF Value™: ₨76.13 vs. price of ₨92.30 (21.2% above fair value)
Industry Position: 9.8% below the Drug Manufacturers median (#417 of 927)
No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
73GF Score
Get the complete analysis for KAR:SEARL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:SEARL has been successfully added to your 
